{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jarsberg LG"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","National Institutes of Health","NIGMS NIH HHS"],"pagination":["e0250586"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8099102"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(5)"],"pubmed_abstract":["<h4>Introduction</h4>Contemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.<h4>Methods</h4>We characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the en"],"journal":["PloS one"],"pubmed_title":["Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region."],"pmcid":["PMC8099102"],"funding_grant_id":["P41 GM103493","R01 AI104589","1R01AI104589","GM103493"],"pubmed_authors":["Sigal GB","Weiner MH","Smith RD","Jarsberg LG","Wright AT","Jacobs JM","Shi T","Gritsenko MA","Kedia K","Wendler J","Lewinsohn DM","Piehowski PD","Nahid P","Keane J"],"additional_accession":[]},"is_claimable":false,"name":"Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.","description":"<h4>Introduction</h4>Contemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.<h4>Methods</h4>We characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the en","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-04-07T14:39:17.203Z","creation":"2025-02-19T02:15:24.947Z"},"accession":"S-EPMC8099102","cross_references":{"pubmed":["33951066"],"doi":["10.1371/journal.pone.0250586"]}}